The new EANM paediatric dosage card: additional notes with respect to F-18.

Introduction: The previously published European Association of Nuclear Medicine (EANM) paediatric dosage card recommends 70 MBq F-18 or F-18 Fluoro-2-Deoxyglucose (F-18-FDG) as the "minimum recommended activity".

Discussion: Two recent publications demonstrate that when utilising F-18-labelled radiopharmaceuticals the administration of lower activities for small children is possible without losing image quality.

Conclusion: In the light of these findings the EANM dosimetry and paediatrics committee have decided to reduce the value for the "minimum recommended activity" for both F-18 and F-18-FDG to 26 MBq for 2D- and 14 MBq for 3D-acquisitions.

The new EANM paediatric dosage card.

Introduction: In a recent publication, Jacobs et al. proposed the use of three tracer-dependent dosage cards for paediatric nuclear medicine.

Materials And Methods: Based upon this work, the EANM dosimetry and paediatrics committees introduce a condensed and revised version of this dosage card for major nuclear medicine paediatric diagnostic procedures, replacing the previous card by Piepsz et al.

The impact of PET and SPECT on dosimetry for targeted radionuclide therapy.

Targeted radionuclide therapy (TRT) is an increasingly used treatment modality for a range of cancers. To date, few treatments have involved the use of dosimetry either to plan treatment or to retrospectively ascertain the absorbed dose delivered during treatment. Also the correlation between absorbed dose and biological effect has been difficult to establish.

Patient dosimetry in radionuclide therapy: the whys and the wherefores.

The importance and methodology of contemporary patient dosimetry in well-established radionuclide therapies are reviewed. The different protocols used for radioiodine treatment of thyrotoxicosis are discussed. Special attention is paid to patient dosimetry in the largest safe dose approach for curative radioiodine therapy of thyroid remnants and metastases in the post-surgical treatment of differentiated thyroid cancer.